Rapid Low Cost Phenotypic Antibiotic Susceptibility Testing.
Award amount
$2,989,713Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Specific Diagnostics, Inc.
- Proposal award date
- 2017-02-07
- Contract end date
- 2020-01-31
- UEI
- N7RLPSHLM4E5
- Solicitation number
- PAR14-088
- Topic code
- NIAID
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Rapid bacteriophage susceptibility testing using small molecule sensor technology
- Rapid Low Cost Phenotypic Antibiotic Susceptibility Testing
- Combining faster detection with ID: a new paradigm for mycobacterial culture
- Inhibitors of isoprenoid synthesis for antibacterial therapy
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
5 SBIR/STTR records share this UEI (2013–2021). Reported award amounts total $9,341,541. Reported amounts are not federal obligations.
Phases: Phase II – Direct to Phase II, Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense